Everest Medicines Ltd. (HK:1952)
:1952
Total Valuation
Everest Medicines Ltd. has a market cap or net worth of HK$13.47B. The enterprise value is HK$11.14B.
Market CapHK$13.47B
Enterprise ValueHK$11.14B
Share Statistics
Everest Medicines Ltd. has 353,581,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding353,581,150
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Everest Medicines Ltd.’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -3.00%.
Return on Equity (ROE)-0.05
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-3.00%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee2.50M
Profits Per Employee-436.18K
Employee Count665
Asset Turnover0.24
Inventory Turnover7.95
Valuation Ratios
The current PE Ratio of Everest Medicines Ltd. is ―. Everest Medicines Ltd.’s PEG ratio is 0.52.
PE Ratio―
PS Ratio6.72
PB Ratio2.11
Price to Fair Value2.11
Price to FCF-64.85
Price to Operating Cash Flow-59.52
PEG Ratio0.52
Income Statement
In the last 12 months, Everest Medicines Ltd. had revenue of 1.66B and earned -290.06M in profits. Earnings per share was -0.86.
Revenue1.66B
Gross Profit998.84M
Operating Income-376.32M
Pretax Income-582.88M
Net Income-290.06M
EBITDA-223.85M
Earnings Per Share (EPS)-0.86
Cash Flow
In the last 12 months, operating cash flow was -181.47M and capital expenditures -24.36M, giving a free cash flow of -205.84M billion.
Operating Cash Flow-181.47M
Free Cash Flow-205.84M
Free Cash Flow per Share-0.58
Dividends & Yields
Everest Medicines Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.73
52-Week Price Change-24.18%
50-Day Moving Average37.78
200-Day Moving Average50.83
Relative Strength Index (RSI)51.91
Average Volume (3m)3.13M
Important Dates
Everest Medicines Ltd. upcoming earnings date is Sep 2, 2026, Before Open (Confirmed).
Last Earnings DateMar 25, 2026
Next Earnings DateSep 2, 2026
Ex-Dividend Date―
Financial Position
Everest Medicines Ltd. as a current ratio of 4.89, with Debt / Equity ratio of 18.05%
Current Ratio4.89
Quick Ratio4.77
Debt to Market Cap0.08
Net Debt to EBITDA8.07
Interest Coverage Ratio-16.60
Taxes
In the past 12 months, Everest Medicines Ltd. has paid -292.82M in taxes.
Income Tax-292.82M
Effective Tax Rate0.50
Enterprise Valuation
Everest Medicines Ltd. EV to EBITDA ratio is -41.85, with an EV/FCF ratio of -54.37.
EV to Sales5.64
EV to EBITDA-41.85
EV to Free Cash Flow-54.37
EV to Operating Cash Flow-85.20
Balance Sheet
Everest Medicines Ltd. has HK$1.59B in cash and marketable securities with HK$708.72M in debt, giving a net cash position of HK$877.19M billion.
Cash & Marketable SecuritiesHK$1.59B
Total DebtHK$708.72M
Net CashHK$877.19M
Net Cash Per ShareHK$2.48
Tangible Book Value Per ShareHK$9.57
Margins
Gross margin is 69.11%, with operating margin of -22.64%, and net profit margin of -17.45%.
Gross Margin69.11%
Operating Margin-22.64%
Pretax Margin-35.06%
Net Profit Margin-17.45%
EBITDA Margin-13.46%
EBIT Margin-22.64%
Analyst Forecast
The average price target for Everest Medicines Ltd. is HK$55.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$55.00
Price Target Upside6.80% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast102.73%
EPS Growth Forecast38.42%